Population Pharmacokinetics of Tigecycline in Healthy Volunteers

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of clinical pharmacology

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270007300263PMID 17519399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

  2005influential reference
• Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations

  2005cited by this paper
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Tigecycline

  2005influential reference
• Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

  2005cited by this paper
• Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects

  2005influential reference
• The glycylcyclines: a comparative review with the tetracyclines.

  2004influential reference
• In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria

  2000cited by this paper
• Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

  2000cited by this paper
• In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936)

  1999cited by this paper
• Fluxes and accumulation of tetracyclines by human blood cells.

  1991cited by this paper
• Some suggestions for measuring predictive performance

  1981cited by this paper
• Drug diffusion and bioavailability: tetracycline metallic chelation.

  1975cited by this paper
• Interaction of tetracylines with ribosomal subunits from Escherichia coli. A fluorometric investigation.

  1973cited by this paper

• Population Pharmacokinetics of Tigecycline and Implications for Individualized Therapy Optimization: A Systematic Review

  2025cites this paper
• Treatment of MRSA Infection: Where are We?

  2024cites this paper
• Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling

  2024cites this paper
• Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients

  2022cites this paper
• Population Pharmacokinetics of Tigecycline: A Systematic Review

  2022cites this paper
• DDDT_A_365512 1885..1896

  2022cites this paper
• Combination Treatment with Intravenous Tigecycline and Intraventricular and Intravenous Colistin in Postoperative Ventriculitis Caused by Multidrug-resistant Acinetobacter baumannii

  2019cites this paper
• Determination of tigecycline in human plasma by LC-MS/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia.

  2018cites this paper
• Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

  2018cites this paper
• Nonlinear Protein Binding: Not What You Think.

  2018cites this paper
• Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

  2018cites this paper
• Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?

  2017cites this paper
• Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects

  2017cites this paper
• Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults.

  2014cites this paper
• Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects

  2014cites this paper
• Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid

  2013cites this paper
• Treatment of infection caused by Borrelia burgdorferi sensu lato

  2011cites this paper
• Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma.

  2011cites this paper
• Low Tigecycline Concentrations in the Cerebrospinal Fluid of a Neutropenic Patient with Inflamed Meninges

  2010cites this paper
• Review of Tigecycline: Focus on Clinical Utilization

  2010cites this paper
• Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria.

  2010cites this paper
• Exposure-response analyses of tigecycline tolerability in healthy subjects.

  2009cites this paper
• Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline

  2009cites this paper
• Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.

  2009cites this paper
• Tigecycline: an overview and update

  2009cites this paper
• In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline.

  2009cites this paper
• New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus.

  2009cites this paper
• Microbiological and Pharmacological Principles of Recent Antibiotic Therapy

  2009cites this paper
• Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.

  2009cites this paper
• Establishing the role of tigecycline in an era of antimicrobial resistance

  2008cites this paper
• A review of tigecycline--the first glycylcycline.

  2008cites this paper
• UNIVERSITY OF FLORIDA THESIS OR DISSERTATION FORMATTING TEMPLATE

  2008cites this paper
• Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.

  2008cites this paper
• New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients.

  2007cites this paper